 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
92 News |  |
- ||||| natural killer cell p46-related protein / Innate, AstraZeneca
Licensing / partnership: $IPH $IPHA Innate Pharma has two ongoing partnerships : one with AZN and one with SANOFI, focused on developing multispecific antibodies, oncology oriented; only one target was disclosed : NKp46, the major NK cell specific activating receptor, a favorite of Pr Eric Vivier, CSO (Twitter) - Sep 15, 2020
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, natural killer cell p46-related protein / Innate, AstraZeneca, Rituxan (rituximab) / Roche, Biogen
Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1132;
In vivo, they induced NK cell accumulation in tumors and promoted tumor clearance in preclinical mouse models of solid and invasive cancers. Our multispecific technology provides a versatile platform with many different format options and the potential to co-engage up to three activating receptors on NK cells and two different tumor antigens on cancer cells.
- || natural killer cell p46-related protein / Innate
#InnatePharma announces publication in Cell on innovative multifunctional #NKp46 #NKCellEngagers (#NKCEs) https://t.co/PvvI8itrfO (Twitter) - May 31, 2019
- |||||| natural killer cell p46-related protein / Innate
Preclinical: *SLIDE SET 5* Dr Mathieu Blery #immunologist @InnatePharma @Immunopole talks @ #TIMO2019 #Halle switching to #NKp46 #bispecific/NK-engager/preclinical model human Raji cells/Role of Fc important/Fc optimized @sitcancer #FinishCancer @AstraZeneca @univamu @Inserm (Twitter) - Apr 26, 2019